GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (FRA:IGS1) » Definitions » Cyclically Adjusted Revenue per Share

IGC Pharma (FRA:IGS1) Cyclically Adjusted Revenue per Share : €0.12 (As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is IGC Pharma Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

IGC Pharma's adjusted revenue per share for the three months ended in Dec. 2024 was €0.003. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.12 for the trailing ten years ended in Dec. 2024.

During the past 12 months, IGC Pharma's average Cyclically Adjusted Revenue Growth Rate was -33.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -30.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -40.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of IGC Pharma was -30.70% per year. The lowest was -58.00% per year. And the median was -42.65% per year.

As of today (2025-05-24), IGC Pharma's current stock price is €0.284. IGC Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was €0.12. IGC Pharma's Cyclically Adjusted PS Ratio of today is 2.37.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of IGC Pharma was 3.97. The lowest was 0.02. And the median was 0.75.


IGC Pharma Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for IGC Pharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGC Pharma Cyclically Adjusted Revenue per Share Chart

IGC Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.86 0.42 0.35 0.18 0.17

IGC Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.17 0.15 0.13 0.12

Competitive Comparison of IGC Pharma's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, IGC Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IGC Pharma's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGC Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where IGC Pharma's Cyclically Adjusted PS Ratio falls into.


;
;

IGC Pharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, IGC Pharma's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.003/133.1571*133.1571
=0.003

Current CPI (Dec. 2024) = 133.1571.

IGC Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201503 0.096 99.621 0.128
201506 0.112 100.684 0.148
201509 0.122 100.392 0.162
201512 0.061 99.792 0.081
201603 0.073 100.470 0.097
201606 0.011 101.688 0.014
201609 0.006 101.861 0.008
201612 0.009 101.863 0.012
201703 0.004 102.862 0.005
201706 0.002 103.349 0.003
201709 0.007 104.136 0.009
201712 0.023 104.011 0.029
201803 0.030 105.290 0.038
201806 0.041 106.317 0.051
201809 0.022 106.507 0.028
201812 0.029 105.998 0.036
201903 0.035 107.251 0.043
201906 0.037 108.070 0.046
201909 0.042 108.329 0.052
201912 0.013 108.420 0.016
202003 0.001 108.902 0.001
202006 0.013 108.767 0.016
202009 0.003 109.815 0.004
202012 0.002 109.897 0.002
202103 0.002 111.754 0.002
202106 0.001 114.631 0.001
202109 0.001 115.734 0.001
202112 0.002 117.630 0.002
202203 0.002 121.301 0.002
202206 0.004 125.017 0.004
202209 0.004 125.227 0.004
202212 0.006 125.222 0.006
202303 0.003 127.348 0.003
202306 0.010 128.729 0.010
202309 0.005 129.860 0.005
202312 0.003 129.419 0.003
202403 0.004 131.776 0.004
202406 0.003 132.554 0.003
202409 0.005 133.029 0.005
202412 0.003 133.157 0.003

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


IGC Pharma  (FRA:IGS1) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

IGC Pharma's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.284/0.12
=2.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of IGC Pharma was 3.97. The lowest was 0.02. And the median was 0.75.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


IGC Pharma Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of IGC Pharma's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


IGC Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (FRA:IGS1) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

IGC Pharma Headlines

No Headlines